180 related articles for article (PubMed ID: 15008344)
41. In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeasts.
Mondello F; De Bernardis F; Girolamo A; Salvatore G; Cassone A
J Antimicrob Chemother; 2003 May; 51(5):1223-9. PubMed ID: 12668571
[TBL] [Abstract][Full Text] [Related]
42. In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study.
Lei J; Xu J; Wang T
J Mycol Med; 2018 Jun; 28(2):310-313. PubMed ID: 29685520
[TBL] [Abstract][Full Text] [Related]
43. Antifungal susceptibilities of Candida species isolated from the patients with vaginal candidiasis.
Nagashima M; Yamagishi Y; Mikamo H
J Infect Chemother; 2016 Feb; 22(2):124-6. PubMed ID: 26627336
[TBL] [Abstract][Full Text] [Related]
44. Species distribution and susceptibility of Candida isolates from patient with vulvovaginal candidiasis in Southern China from 2003 to 2012.
Liu XP; Fan SR; Peng YT; Zhang HP
J Mycol Med; 2014 Jun; 24(2):106-11. PubMed ID: 24746725
[TBL] [Abstract][Full Text] [Related]
45. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program.
Pfaller MA; Jones RN; Messer SA; Edmond MB; Wenzel RP
Diagn Microbiol Infect Dis; 1998 May; 31(1):327-32. PubMed ID: 9597393
[TBL] [Abstract][Full Text] [Related]
46. Genotyping and Persistence of Candida albicans from Pregnant Women with Vulvovaginal Candidiasis.
Tapia CV; Hermosilla G; Fortes P; Alburquenque C; Bucarey S; Salinas H; Rodas PI; Díaz MC; Magne F
Mycopathologia; 2017 Apr; 182(3-4):339-347. PubMed ID: 27882525
[TBL] [Abstract][Full Text] [Related]
47. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients.
Saag MS; Fessel WJ; Kaufman CA; Merrill KW; Ward DJ; Moskovitz BL; Thomas C; Oleka N; Guarnieri JA; Lee J; Brenner-Gati L; Klausner M
AIDS Res Hum Retroviruses; 1999 Nov; 15(16):1413-7. PubMed ID: 10555103
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic efficacy of posaconazole against isolates of Candida albicans with different susceptibilities to fluconazole in a vaginal model.
González GM; Robledo E; Saldívar D; González G; Bosques F; Garza E
Med Mycol; 2007 May; 45(3):221-4. PubMed ID: 17464843
[TBL] [Abstract][Full Text] [Related]
49. Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction - impact of two decades.
Bulik CC; Sobel JD; Nailor MD
Mycoses; 2011 Jan; 54(1):34-8. PubMed ID: 19563489
[TBL] [Abstract][Full Text] [Related]
50. Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis.
Cernicka J; Subik J
Int J Antimicrob Agents; 2006 May; 27(5):403-8. PubMed ID: 16621465
[TBL] [Abstract][Full Text] [Related]
51. Multilocus sequence typing analysis of Candida africana from vulvovaginal candidiasis.
Zhu YX; Shi Y; Fan SR; Liu XP; Yang J; Zhong SL
BMC Infect Dis; 2019 May; 19(1):461. PubMed ID: 31117966
[TBL] [Abstract][Full Text] [Related]
52. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
Panizo MM; Reviákina V; Dolande M; Selgrad S
Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of the E test for fluconazole susceptibility testing of Candida albicans isolates from oropharyngeal candidiasis.
Dannaoui E; Colin S; Pichot J; Piens MA
Eur J Clin Microbiol Infect Dis; 1997 Mar; 16(3):228-32. PubMed ID: 9131326
[TBL] [Abstract][Full Text] [Related]
54. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society.
Mendling W; Brasch J; ; ; ;
Mycoses; 2012 Jul; 55 Suppl 3():1-13. PubMed ID: 22519657
[TBL] [Abstract][Full Text] [Related]
55. In vitro antifungal sensitivity of fluconazole, clotrimazole and nystatin against vaginal candidiasis in females of childbearing age.
Khan F; Baqai R
J Ayub Med Coll Abbottabad; 2010; 22(4):197-200. PubMed ID: 22455297
[TBL] [Abstract][Full Text] [Related]
56. Fluconazole-Resistant Candida albicans Vaginal Infections at a Referral Center and Treated With Boric Acid.
File B; Sobel R; Becker M; Nyirjesy P
J Low Genit Tract Dis; 2023 Jul; 27(3):262-265. PubMed ID: 36961480
[TBL] [Abstract][Full Text] [Related]
57. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.
Sobel JD; Wiesenfeld HC; Martens M; Danna P; Hooton TM; Rompalo A; Sperling M; Livengood C; Horowitz B; Von Thron J; Edwards L; Panzer H; Chu TC
N Engl J Med; 2004 Aug; 351(9):876-83. PubMed ID: 15329425
[TBL] [Abstract][Full Text] [Related]
58. Clinical and mycological efficacy of single-day oral treatment with itraconazole (400 mg) in acute vulvovaginal candidosis.
Urünsak M; Ilkit M; Evrüke C; Urünsak I
Mycoses; 2004 Oct; 47(9-10):422-7. PubMed ID: 15504127
[TBL] [Abstract][Full Text] [Related]
59. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans.
Laguna F; Rodríguez-Tudela JL; Martínez-Súarez JV; Polo R; Valencia E; Díaz-Guerra TM; Dronda F; Pulido F
Clin Infect Dis; 1997 Feb; 24(2):124-30. PubMed ID: 9114134
[TBL] [Abstract][Full Text] [Related]
60. [Analysis of the diagnosis and treatment of recurrent vulvovaginal candidiasis in 80 cases].
Yuan XR; Li HW; Yuan L; Fan LZ
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Oct; 30(10):2413-4, 2416. PubMed ID: 20965860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
